Patients with COPD are usually given LTOT in the advanced stage of the disease and long Background -To date only two controlled studies have been published on the effects term survival in such patients, despite oxygen treatment, remains poor. [1] [2] [3] [4] It has been sugof domiciliary oxygen treatment on survival in patients with chronic obstructive gested that LTOT should be prescribed earlier in the natural history of the disease, 5 6 and in pulmonary disease (COPD) with advanced respiratory failure. The survival some countries oxygen is also prescribed to patients with moderate hypoxaemia (Pa 2 in such patients despite oxygen treatment remains poor. The prescription of long 7.4-8.7 kPa (56-65 mmHg)).
body mass index (BMI), spirometric values, blood gas tensions, and haematocrit at entry to the study are shown in table 1. All patients as lasting more than six months. Patients on suffered from severe airflow limitation with LTOT received oxygen from an oxygen conmean (SD) forced expiratory volume in one centrator at a flow rate adjusted to raise resting second (FEV 1 ) 0.83 (0.28) l. Pa 2 above 8.7 kPa (65 mmHg). The pre-
The control and treatment groups were well scribed oxygen breathing time was at least 17 matched in all measured variables. The only hours per 24 hours. The compliance with the significant difference at entry to the study was treatment was checked by reading the oxygen the value of Pa 2 (table 1) . To check for the meter built into the oxygen concentrator.
influence of Pa 2 on survival the Cox's rePatients were strongly advised to stop smoking gression coefficients corresponding to the inand all declared to be non-smokers at the time dependent variable Pa 2 were calculated of prescription of oxygen. Informed consent separately for each group and provided no was obtained from each patient. The protocol evidence that the Pa 2 value influenced the of the study was approved by the ethics comsurvival of the patients in the study. mittee of the Institute.
In the group receiving LTOT the Pa 2 while After allocation to the control or treatment breathing oxygen was increased in all patients groups patients were followed closely for at to more than 8.7 kPa (65 mmHg) (mean Pa 2 / least three years or until death. They were O 2 9.9 (1.1) kPa (74.0 (7.9) mmHg)). Only in visited at home monthly by a respiratory nurse seven patients (three of whom were survivors) and were seen once every three months in an was the Pa 2 increased by less than 1 kPa while outpatient clinic by the physician responsible breathing oxygen. The mean time spent breathfor LTOT, being admitted to hospital for other ing oxygen, calculated from the oxygen contreatment as necessary. There were no dropouts centrator meter readings, was 13.5 (4.4) hours/ during the study. All deaths and causes of day. death were recorded. Each living patient was Seventy patients died during the observation contacted at the end of the study in December period, 32 in the control group and 38 in 1994 by a respiratory nurse.
the LTOT group. The causes of death are presented in table 2. Most of the deaths in both   groups were due to progression of the COPD. Means and standard deviations of measured
The cumulative survival rate of the total variables were calculated. Differences between group in the first year was 88%, in the second groups were assessed using an unpaired t test, year 77%, and in the third year 66%. Survival p values of <0.05 being considered statistically significant. Survival analysis was performed using Cox's proportional hazards analysis for the factors that might influence survival. 11 The model also provides the possibility for checking the statistical significance of the influences on survival of one or more variables studied. The statistical significance of the differences between two groups was assessed using Cox's regression model and checked by the WilcoxonMann-Whitney type non-parametric test. In particular, the Gehan-Wilcoxon statistic was used to confirm the lack of difference in survival between the control and treatment groups. Statistica and NCSS packages were used for the computation procedures. Figure 2 shows the survival curves of our patients (in the LTOT and control groups) superimposed on the survival curves of the MRC and NOTT studies. The survival of our patients with COPD with moderate hypoxaemia in both the control and treatment groups was better than of those with severe hypoxaemia in the MRC and NOTT studies; however, there is a considerable overlap.
The differences in the studied variables between survivors and non-survivors in the total group are presented in table 3. Patients who survived were significantly younger (59.4 vs 62.9 years, p=0.02), had better lung function (VC 2.06 l vs 1.85 l, p=0.038 and FEV 1 0.89 l vs 0.78 l, p<0.001), and higher BMI (25.1 kg/ m 2 vs 22.5 kg/m 2 , p<0.001) than non-survivors. The differences in the studied variables between survivors and non-survivors in the con- group better lung function (VC 2.12 l in survivors vs 1.80 l in non-survivors (p=0.037) ences in survival in patients using oxygen for 15 or more hours/day compared with those less compliant (p=0.376). When oxygen use was stratified there were 10 survivors and 11 nonanalysis using Cox's regression model showed survivors who breathed oxygen for less than 12 no differences in survival between oxygen hours, 11 patients in each group who used treated and control groups (fig 1) . The hazard oxygen for 12-15 hours, and only nine survivors ratio to be a member of the control group is compared with 16 non-survivors who breathed equal to 0.916 with a 95% confidence interval oxygen for more than 15 hours/day. of 0.571 to 1.471 (the value 1, representing an
The mean Pa 2 in our patients was 8.0 kPa equal hazard for LTOT and control groups, (60.4 mmHg) with 74 patients having a Pa 2 is well covered by this interval). Additional of Ζ8.0 kPa and 61 patients with a Pa 2 of analysis using the Gehan-Wilcoxon statistic >8.0 kPa. No differences in survival were found with the value of −0.018 (p=0.49) confirmed in these subgroups of patients ( fig 3) . We also the lack of difference between the control and treatment groups.
found that, among the LTOT group who sur- logical variable studied predicted significant differences in survival.
vived, seven resumed smoking as judged by an elevated carboxyhaemoglobin level. Thirty nine Discussion The prescription of LTOT to patients with patients (29%) used long term steroids (more than six months), seven inhaled steroids, six COPD with moderate hypoxaemia did not prolong life. Moreover, within the oxygen treated intramuscular, and 26 oral preparations. Long term steroids were used by twice as many group no correlation was found between oxygen use and survival. patients who did not survive (n=26) as survivors (n=13), but the difference did not reach
The beneficial effect of LTOT in preventing the progression of pulmonary hypertension is statistical significance (table 3) . Using Cox's proportional hazards analysis well known [12] [13] [14] but this treatment does not influence the progression of the airflow limon the pooled sample (135 patients) we found that the cut off value of FEV 1 of 0.8 l was itation. [15] [16] [17] To date only two controlled studies have been reported on the effects of long term significantly related to survival rates (fig 4) . Survival rates also improved significantly with oxygen breathing in patients with COPD with advanced respiratory failure -the MRC and increasing BMI, patients with a BMI of >25 kg/ m 2 having higher survival rates than those with NOTT studies 1 2 -both of which found that breathing oxygen for more than 15 hours/day a BMI of <20 kg/m 2 ( fig 5) . We have also found that BMI was closely related to FEV 1 (r= substantially prolonged survival. The longer the oxygen breathing time the better survival 0.345, p<0.001). Additional analysis based on Cox's regression model was performed to estab-was observed.
Although the upper limit of Pa 2 for inclusion lish the influence of both parameters on survival, taking into account the positive in these studies was set at 8 kPa (60 mmHg), most of the patients had a Pa 2 of less than correlation between them. The analysis with two independent variables showed that, if BMI 7.3 kPa (55 mmHg). In the MRC study the mean Pa 2 on air was only 6.7 kPa and FEV 1 were mutually adjusted, then only BMI had a significant positive influence on (50.4 mmHg) for the treated group and 6.9 kPa (51.5 mmHg) for the controls, whereas in the survival. Corresponding p values were 0.14 for FEV 1 and 0.035 for BMI. Hazard ratios (95% NOTT study it was 6.8 kPa (50.8 mmHg) for the continuous therapy group and 6.9 kPa confidence interval) estimated by the Cox's group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from (51.5 mmHg) for the nocturnal oxygen group. such as those in the MRC and NOTT studies, Mean Pa 2 in our patients was much higher but not to our patients. There was, however, (8.0 kPa (60.4 mmHg)). Although it might a considerable overlap in the survival of our have been anticipated, no differences in survival patients and those from the abovementioned were found in subgroups of patients with Pa 2 studies. Ζ8 kPa and >8.0 kPa at entry to the study.
Patients receiving LTOT increased their Our treated and control groups were well Pa 2 on average by 2 kPa while breathing oxymatched at the beginning of the study. The gen. Almost all improved their oxygenation by only statistically significant difference (al-at least 1 kPa, which is in accordance with the though clinically trivial) between the groups UK guidelines for prescribing oxygen. 23 An was in Pa 2 which was lower in the LTOT equal number of non-responders was found group. This difference was probably due to a among the survivors and non-survivors, sugnarrow range (only 1.3 kPa (10 mmHg)) of gesting that this factor did not influence the inclusion Pa 2 values. Such a range restricted survival. the standard deviation, thereby increasing the This comparison of our data with that in significance of small differences in mean values. the literature clearly confirms that survival in Moreover, the Pa 2 did not influence the sur-patients with COPD is influenced by airway vival in either group or the study group as a limitation and that LTOT prolongs life only whole, which is the best evidence that the when severe hypoxaemia ensues. baseline differences were not important.
In our patients survival depended on lung In the two landmark studies 1 2 survival was function and age at entry to the study. Patients positively associated with the number of hours who survived had better preserved lung funcof oxygen breathing. In our study compliance tion and were significantly younger. In many with the treatment was similar to that of the previous studies the age has also proved to be MRC trial. However, we observed no differ-a significant predictor of survival. 4 21 22 24 ences between oxygen use in survivors (12.7 In a number of studies of patients with hours/day) and non-survivors (14.2 hours/day). COPD 25 26 survival was influenced by the body When we analysed a subgroup of patients who mass. Undernourished patients did not do so breathed oxygen for more than 15 hours/day well as those who were overweight 20 and this there were more non-survivors than survivors effect was independent of the lung function. 26 in that group. This finding may be explained Also, our patients who survived had a sigby the fact that surviving patients were younger, nificantly higher BMI than those who did not had better lung function, and did not feel the survive and the survival rate improved with need to comply with the prescribed treatment increasing body mass independently of FEV 1 , (17 hours and more). Similarly, in a study by as well as after adjusting BMI for FEV 1 , similar the ANTADIR group 65% of patients with to the results of the IPPB trial. We have found that, after mutually adjusting daily oxygen use to below 15 hours because BMI and FEV 1 , only BMI proved to have a they found the longer treatment not necessary. 18 significant influence on survival. This may be From two recent studies from Sweden 19 and explained by the extremely narrow range of the ANTADIR group in France 20 it appears that very low FEV 1 values. However, FEV 1 proved survival in patients with a higher prescription of to be significantly lower in non-survivors and oxygen is inferior to that in patients with a the value of 0.8 l resulted in significant differlower oxygen prescription and may reflect the ences in survival in those with less and more physician's perception of the severity of the advanced airway limitation. disease.
Another factor that should be taken into Survival in our group was similar to that of account in studying survival is stopping smokpatients in the IPPB trial with a similar degree ing. It is well known that quitting smoking of airflow limitation and no hypoxaemia. 21 Surslows the decline in FEV 1 27 28 and improves the vival in both the treatment and control groups survival, although such an influence becomes was better than survival of the patients in the apparent only after approximately six years of MRC trial 1 with more advanced airflow limfollow up. 29 All our patients declared to be itation (FEV 1 0.76 l in oxygen treated group, non-smokers when starting LTOT, however 0.63 l in controls) and more severe hypoxaemia.
seven had resumed smoking as judged by raised It was also better than the survival of the noccarboxyhaemoglobin level at 1-3 months after turnal oxygen therapy group and similar to the entering the study. All these patients survived. survival in the continuous oxygen treatment
The carboxyhaemoglobin level was not checked group in the NOTT trial.
2 In a comparison of in the control group. It is extremely difficult to patients in the IPPB trial without hypoxaemia draw any conclusion from this finding due to with NOTT patients with the same degree of the limited number of patients in whom we airway limitation, Athonisen has found that the could study these influences. correction of hypoxaemia improved the survival It has been suggested that use of long term rates of the continuous oxygen therapy group corticosteroids in women with COPD may adto the rate of survival of patients with no blood versely affect survival. 30 Such treatment was gas disturbances, as opposed to the less faprescribed in 29% of our patients and twice vourable survival of the nocturnal oxygen as many patients receiving steroids died as group. 22 The correction of hypoxaemia in the survived. However, this difference did not reach MRC trial also improved the survival in oxygen statistical significance. As we included only treated patients compared with controls.
1 Oxygen treatment was of benefit to the patients patients with COPD with fixed airway ob- 
